Form 4: CalciMedica Director Eric Bjerkhot Granted Stock Options

Director Eric Bjerkhot acquired 10,000 stock options in CalciMedica, Inc. on August 27, 2024.

Summary

• Eric Bjerkhot, a director of CalciMedica, Inc., was granted 10,000 stock options on August 27, 2024.
• The exercise price of these options is $4.16.
• The options expire on August 26, 2034.
• The options vest in equal monthly installments over a one-year period following March 28, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no red flags or negative indicators.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, especially in the biotech sector.
• The vesting schedule of 1/12th monthly over one year is a typical vesting arrangement.
• The exercise price of $4.16 would need to be compared to the market price of CalciMedica's stock at the time of the grant to assess its competitiveness.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates